<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00107666</url>
  </required_header>
  <id_info>
    <org_study_id>CTI-01-C04-201</org_study_id>
    <nct_id>NCT00107666</nct_id>
  </id_info>
  <brief_title>CTI-01 (Ethyl Pyruvate) Safety and Complication Prevention in Cardiac Surgery Patients on Cardiopulmonary Bypass (CPB)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Proof of Concept Clinical Study of CTI-01 in Patients Undergoing Major Cardiac Surgery With Cardiopulmonary Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Critical Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Critical Therapeutics</source>
  <brief_summary>
    <textblock>
      Over 500,000 patients undergo cardiac surgery with CPB in the United States annually.
      Although mortality rates have decreased with advances in perioperative care, many patients
      are affected by postoperative organ dysfunction. The incidence of complications may exceed
      30%. It has been speculated that an exaggerated inflammatory response to surgical trauma and
      the CPB machine are likely causes for this morbidity. Factors predisposing organ dysfunction
      include tissue injury, endotoxemia, and oxidative stress. High risk patients can be
      identified preoperatively through the validated Parsonnet Additive Risk Score. CTI-01 has
      demonstrated potent anti-inflammatory and tissue protection activity in multiple animal
      models of disease including pancreatitis, ischemia-reperfusion injury, sepsis, renal injury,
      and endotoxemia. These findings support its clinical use in critical care medicine including
      cardiac surgery. Patients will receive a total of six doses, administered intravenously just
      prior to and after surgery.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>April 2005</start_date>
  <completion_date>April 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite morbidity endpoint</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory dysfunction</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac dysfunction</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal dysfunction</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal dysfunction</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mental status</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU (Intensive Care Unit)/hospital stay</measure>
  </secondary_outcome>
  <enrollment>150</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Heart Valve Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTI-01 (ethyl pyruvate)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parsonnet additive risk score greater than or equal to 15

          -  Scheduled CABG (coronary artery bypass grafting) and/or cardiac valve repair or
             replacement surgery using cardiopulmonary bypass

        Exclusion Criteria:

          -  Emergency cardiac surgery

          -  Significant concomitant surgery

          -  Minimally invasive or thoracic surgical approach

          -  Preoperative mechanical assist device

          -  Body weight &lt;50 kg or &gt;140 kg

          -  Active systemic infection

          -  Creatinine &gt;3.0 mg/dL

          -  History of hematologic or coagulation disorders

          -  History of malignancy (past year)or organ transplantation

          -  Use of immunosuppressive drugs or current immunosuppressed condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Newman, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Critical Therapeutics Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saddleback Memorial Medical Center</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Support Personnel</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Regional Medical Center</name>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <zip>21801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University - Brody School of Medicine</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chester County Hospital - The Cardiovasular Center</name>
      <address>
        <city>West Chester</city>
        <state>Pennsylvania</state>
        <zip>19380</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Episcopal Hospital/Texas Heart Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Health System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin - VA Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Parsonnet V, Dean D, Bernstein AD. A method of uniform stratification of risk for evaluating the results of surgery in acquired adult heart disease. Circulation. 1989 Jun;79(6 Pt 2):I3-12. Erratum in: Circulation 1990 Sep;82(3):1078.</citation>
    <PMID>2720942</PMID>
  </reference>
  <reference>
    <citation>Bennett-Guerrero E, Ayuso L, Hamilton-Davies C, White WD, Barclay GR, Smith PK, King SA, Muhlbaier LH, Newman MF, Mythen MG. Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery. JAMA. 1997 Feb 26;277(8):646-50.</citation>
    <PMID>9039883</PMID>
  </reference>
  <reference>
    <citation>Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R, Czura CJ, Fink MP, Tracey KJ. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12351-6. Epub 2002 Sep 3.</citation>
    <PMID>12209006</PMID>
  </reference>
  <reference>
    <citation>Woo YJ, Taylor MD, Cohen JE, Jayasankar V, Bish LT, Burdick J, Pirolli TJ, Berry MF, Hsu V, Grand T. Ethyl pyruvate preserves cardiac function and attenuates oxidative injury after prolonged myocardial ischemia. J Thorac Cardiovasc Surg. 2004 May;127(5):1262-9.</citation>
    <PMID>15115981</PMID>
  </reference>
  <reference>
    <citation>Fink MP. Ethyl pyruvate: a novel anti-inflammatory agent. Crit Care Med. 2003 Jan;31(1 Suppl):S51-6. Review.</citation>
    <PMID>12544977</PMID>
  </reference>
  <verification_date>March 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2005</study_first_submitted>
  <study_first_submitted_qc>April 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2005</study_first_posted>
  <last_update_submitted>March 15, 2006</last_update_submitted>
  <last_update_submitted_qc>March 15, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2006</last_update_posted>
  <keyword>Coronary artery bypass grafting</keyword>
  <keyword>Heart valve prosthesis implantation</keyword>
  <keyword>Cardiopulmonary bypass</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Endotoxemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

